| Stereochemistry | ACHIRAL |
| Molecular Formula | C18H22N6O3S |
| Molecular Weight | 402.471 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NS(=O)(=O)C1=CC=C(NC2=NC(OCC3CCCCC3)=C4NC=NC4=N2)C=C1
InChI
InChIKey=OWXORKPNCHJYOF-UHFFFAOYSA-N
InChI=1S/C18H22N6O3S/c19-28(25,26)14-8-6-13(7-9-14)22-18-23-16-15(20-11-21-16)17(24-18)27-10-12-4-2-1-3-5-12/h6-9,11-12H,1-5,10H2,(H2,19,25,26)(H2,20,21,22,23,24)
NU6102 is a potent CDK1/cyclin B and CDK2/cyclin A3 inhibitor (IC50 values are 9.5 and 5.4 nM for CDK1/cyclin B and CDK2/cyclin A3 respectively). Antiproliferative agent. Induces G2/M cell cycle arrest. Shows antitumor effects in vivo. NU6102 and its prodrug NU6301 have pharmacological properties consistent with CDK2 inhibition, and represent useful tool molecules for the evaluation of CDK2 as a target in cancer.
Originator
Approval Year
PubMed
Patents
Sample Use Guides
Mice: Mice were
treated with either the maximum administrable dose of
NU6102 i.p. (10 mg/kg in a vehicle of 40% (v/v) polyethylene
glycol400) or i.v. (1 mg/kg i.v. in a vehicle of 10% (v/v) polyethylene
glycol400), or a dose of 10 mg/kg NU6301, equivalent to 8.4 mg/kg NU6102, in sterile saline for both i.v. and i.p.
administration.
Route of Administration:
Other
ACTIVE MOIETY
